Congenital heart disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• SGLT2 3
• SHP2 0
• ACE2 0
• APP 0
• BCL-2 0
• FAK 0
• FGFR 0
• GLP-1 0
• MMP-9 0
• NF1 0
• PI3K 0
• PPAR 0
• STING 0
• TP53 0
• YAP 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Switching cardiomyocyte activity to uncover biology and treat disease. (CARDIOSWITCH)

  Centro Nacional de Investigaciones Cardiovasculares Carlos Iii (F.s.p.)· Madrid, Spain· EU contribution €2,428,125· until Oct 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-IA

  OPTIMISING THE MANUFACTURING PLATFORM FOR INDIVIDUALIZED IPS CELL BASED HEART REPAIR (iNDUCARE)

  Medizinische Hochschule Hannover· Hannover, Germany· EU contribution €7,985,334· until Aug 2030· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Congenital Heart Anomaly Representation and Machine-learning for Screening (CHARMS)

  Imperial College of Science Technology and Medicine· London, United Kingdom· EU contribution €150,000· until Jun 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  Polymer-based Stealth Coating of Hemocompatible and Absorbable Stents (StealthStent)

  Biomodics Aps· Kgs Lyngby, Denmark· EU contribution €2,495,679· until Mar 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Beyond the chromosome: unravelling the interplay between inter-chromosomal genome architecture and mRNA biogenesis (TRANS-3)

  Universita Degli Studi di Torino· Torino, Italy· EU contribution €1,769,998· until Aug 2028

5 of 8 running projects, newest first. Listed amounts together: €19.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 9
• Organoids 6
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 5
• Gene Expression Profiling 12
• Whole Genome Sequencing 11
• Exome Sequencing 58
• Proteomics 16
• Metabolomics 8
• Mass Spectrometry 4
• Immunohistochemistry 3
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 135
• Machine Learning 35
• Deep Learning 26
• Cohort Studies 112
• Genome-Wide Association Study 12

• Causal inference between neurodevelopmental disorders and brain structure among individuals with congenital heart disease: Insights from meta-analysis and Mendelian randomization.

  Ital J Pediatr, Mar 2026

• Genetic Association of Circulating Proteins and Gene Transcripts With Spontaneous Coronary Artery Dissection.

  Circ Genom Precis Med, Jan 2026

• The association between interatrial shunt and subtypes of migraine: a Mendelian randomization study.

  Neurol Sci, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.